Breast Cancer Survivors Learn about the Importance of Early Lymphedema Detection and Intervention with L-Dex Readings
SAN DIEGO, Oct. 30 /PRNewswire/ -- A large number of breast cancer survivors received complimentary L-Dex readings as part of the "Know Your L-Dex" awareness campaign activities at recent Komen Race for the Cure(R) events in Houston and Dallas.
Dr. Walton Taylor, a breast surgeon at the Medical City Dallas Hospital, provided survivors with complimentary readings using an FDA-cleared L-Dex medical device developed by ImpediMed Ltd. (ASX: IPD).
L-Dex readings serve as an aid for medical professionals to clinically assess female breast cancer patients for the early signs of unilateral lymphedema of the arm (swelling that occurs in one arm following breast cancer treatment), potentially before symptoms such as heaviness or visible swelling are present.
"Lymphedema is one of the major concerns of many breast cancer survivors, and it is important that they are educated on the importance of early detection and intervention," said Dr. Taylor. "With the help of ImpediMed's L-Dex devices, medical professionals can now perform pre-operative baseline assessments and conduct ongoing surveillance for the early signs of lymphedema in patients."
"The outcomes of the 'Know Your L-Dex' activities in Texas greatly exceeded our expectations," said Greg Brown, CEO of ImpediMed. "In addition to performing the readings, Dr. Taylor answered survivors' questions about lymphedema and helped Komen Race for the Cure(R) participants to gain a better understanding of the importance of early lymphedema detection and intervention. We look forward to bringing the 'Know Your L-Dex' activities to other markets this quarter and throughout next year."
Additional "Know Your L-Dex" activities are scheduled for November at the Komen San Diego Race for the Cure(R) and the Breast Cancer Network of Strength's Life in Balance: Breast Cancer Survivorship Forum in Chicago.
For additional information about L-Dex or the "Know Your L-Dex" campaign, call 858-412-0199 x1235 or visit http://www.l-dex.com.
Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body and is a key component of the immune system, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that six percent to 40 percent of patients with breast cancer develop lymphedema, and that it often occurs within the first two years after surgery. For some cancer survivors and others at risk, a low level lymphedema can occur 10 years to 15 years following the initial primary treatment and develop into a condition that has a serious impact on overall health and quality of life.
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedence Spectroscopy (BIS) technologies to aid medical providers in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that enable surgeons, oncologists, therapists and radiation oncologists to clinically assess patients for the potential onset of secondary lymphedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may help prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary lymphedema of the arm in female breast cancer patients. For more information, visit http://www.impedimed.com.
Note: ImpediMed's device is not intended to diagnose or predict
lymphedema of an extremity.
Media Contacts: Wendy Lau or Bianca Molina
(212) 845-4272 office
|SOURCE ImpediMed Ltd.|
Copyright©2008 PR Newswire.
All rights reserved